Immunocore Corp (IMCR) - Market Cap to Net Income Ratio

Corporate emblem and logo of Immunocore PLC (IMCR)

The integration of drugs into standard treatment protocols guarantees stable therapy sales for Immunocore Holdings plc (IMCR). The company's historical P/E range visualizes this trend, where -45.10 describes the current status of the metric. Patent protection for T-cell receptors creates a unique monopoly in the uveal melanoma niche, while the commercial launch of targeted products triggers a phase of rapid business growth.

IMCR immunocore.com: Price to Earnings Ratio in the range 07/04/2022 - 11/18/2026

Analytical breakdowns for Immunocore Holdings plc

- market price and analyst price targets:
Comprehensive company analysis:IMCR Immunocore PLC
Manufactured product of Immunocore Holdings plc

The innovativeness of the ImmTAC platform, which creates unparalleled cancer therapy methods, establishes high capitalization potential for Immunocore Holdings plc (IMCR). By analyzing the company's annual P/E, an investor assesses the business value relative to its net income, which allows for the identification of asset overvaluation. This chart reflects the balance between market expectations for a biotechnological breakthrough and the company's actual ability to generate cash flow.

Competing companies

Market Cap to Earnings ImmunityBio IBRX|P/E Multiple JANX|Arcus Biosciences, Inc. (RCUS) - Market Cap to Net Income Ratio|Zymeworks Inc - Price to Earnings Ratio|Tango Therapeutics, Inc. (TNGX) - Market Cap to Earnings|IOVA: Price to Earnings Ratio|Company Value to Net Income IMTX (Immatics)|XNCR: P/E Multiple|CMPX - Business Payback Period|Price to Earnings Ratio replimune.com|Price to Earnings Ratio lyell.com (LYEL)|Price to Earnings Ratio Innate Pharma SA (IPHA)|Price to Earnings Ratio Pyxis PYXS|Compugen Ltd - Price to Earnings Ratio|P/E Multiple IO Biotech Inc. IOBT|STRO - Price to Earnings Ratio|INKT (minktherapeutics.com) - Price to Earnings Multiple|werewolftx.com (HOWL) - Price to Earnings Ratio|Market Cap to Earnings Immix Biopharma, Inc. (IMMX)|Price to Earnings Ratio ALXO|CUE (Cue Biopharma, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio PDSB (PDS Biotechnology)|Market Price to Net Income Ratio SONN|P/E Multiple MAIA (MAIA Biotechnology, Inc.)|Company Value to Net Income LIMN|Lava Tx - P/E Multiple|Market Cap to Earnings NextCure Corporation|Leap Tx (LPTX) - Price to Earnings Ratio|Intensity Therapeutics Inc - Company Value to Net Income|SNSE (Sensei Bio) - P/E Multiple|P/E Multiple Theriva Biologics Inc|Price to Earnings Ratio gritstonebio.com (GRTS)|P/E Multiple Kineta Bio (KA)|NexImmune Inc - Price to Earnings Ratio|turnstonebio.com (TSBX) - Market Cap to Earnings|VCNX: Price to Earnings Ratio|Company Value to Net Income HARP (Harpoon Therapeutics, Inc.)